Last reviewed · How we verify
CD20 positive diffuse large B cell non Hodgkin's lymphoma
Approved treatments
- Mabthera · Roche
- Mabthera · Roche
Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC. - Mabthera · Roche
Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- CD20 positive diffuse large B cell non Hodgkin's lymphoma patent landscape — cliff calendar, originator estates, attackable patents
- CD20 positive diffuse large B cell non Hodgkin's lymphoma treatment landscape brief
- CD20 positive diffuse large B cell non Hodgkin's lymphoma treatment updates RSS
Frequently asked questions about CD20 positive diffuse large B cell non Hodgkin's lymphoma
What drugs treat CD20 positive diffuse large B cell non Hodgkin's lymphoma?
Tracked treatments include Mabthera.
What is the treatment for CD20 positive diffuse large B cell non Hodgkin's lymphoma?
Standard treatment for CD20 positive diffuse large B cell non Hodgkin's lymphoma includes Mabthera. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: CD20 positive diffuse large B cell non Hodgkin's lymphoma patent cliff · CD20 positive diffuse large B cell non Hodgkin's lymphoma CI report
- Treatment: Mabthera · Roche
- Treatment: Mabthera · Roche
- Treatment: Mabthera · Roche
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing